> By the way - why are you so eager to promote this drug - can you please declare any conflict of interests?

The closest thing to a conflict of interest I have is that I am currently seeing great results while taking tirzepatide. I find it significantly easier to choose healthier meals made of whole foods with balanced macros, to eat less in general, and to motivate myself to push back towards the exercise habits I had in my 20s. I have no relation to big pharma, and I have no idea if my index fund tracking retirement plans include Novo Nordisk or Eli Lilly, but if they do, that's the closest thing I have to a financial incentive in these companies doing well.

> we can start with "Risk of Suicidal Thoughts and thoughts of self-harm with medicines known as GLP-1 receptor agonists,1 including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide)"

Please read the content you are linking. It said that there were some reports so they were beginning to perform a review. The article specifically mentions the review was set to conclude in Nov 2023. Upon seeing this, I figured it would be a good idea to see if the results of the review had come out.

It took me one google query to find the results: https://www.ema.europa.eu/en/news/meeting-highlights-pharmac...

> The PRAC has concluded that the available evidence does not support a causal association between the Glucagon-Like Peptide-1 receptor agonists (GLP-1) – dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide – and suicidal and self-injurious thoughts and actions.

So we can scratch that one off the list.